Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
Alzheimer Europe 2025: Prioritising Alzheimer’s Disease policy in Europe
Building upon the findings of a recent CRA report, which synthesised insights from a roundtable of AD experts, Prioritising Alzheimer’s disease policy in...